cdk2in13

I-37 free base is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.

Stevia impurity (13-[(2-O-6-deoxy-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oic acid β-D-glucopyranosyl ester) is a natural product for research related to life sciences. The catalog number is TN6498 and the CAS number is 1309929-72-3.

Bcl-2-IN-13 is a potent inhibitor of Bcl-2, exhibiting an IC50 of 17 nM, and holds potential for use in cancer research [1].

1, 14-tetradecanedioic-2, 2, 13, 13-d4 acid is a deuterated compound of 1, 14-tetradecanedioic acid. 1, 14-tetradecanedioic acid has a CAS number of 821-38-5. Tetradecanedioic acid is a C14 dicarboxylic acid.

8alpha-(2-Methylacryloyloxy)-1-O-methylhirsutinolide 13-O-acetate is a natural product for research related to life sciences. The catalog number is TN3293 and the CAS number is 883872-71-7.

CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).

SARS-CoV-2 3CLpro-IN-13 is a potent inhibitor of the SARS-CoV-2 3CL protease, demonstrating significant anti-coronavirus activity with an IC50 value of 21 nM [1].

COX-2-IN-13 (compound 13e) is a highly potent and selective inhibitor of COX-2, demonstrating a remarkable IC50 value of 0.98 μM. It exhibits strong anti-inflammatory activity and has shown favorable results in vivo acute toxicity studies [1].

SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide. SARS-CoV-2-IN-13 is more stable than niclosamide in human plasma and liver S9 enzymes assay. SARS-CoV-2-IN-13 can improve bioavailability and half-life when administered orally. SARS-CoV-2-IN-13 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.057 μM [1].

Polyketide synthase 13-IN-2 (comp 42) is a potent inhibitor of polyketide synthase 13 in Mycobacterium tuberculosis. It demonstrates a minimum inhibitory concentration (MIC) of 0.25 μg/mL [1].

CDK/HDAC-IN-2 is a potent dual HDAC/CDK inhibitor that acts on HDAC1 (IC50: 6.4 nM), HDAC2 (IC50: 0.25 nM), HDAC3 (IC50: 45 nM), HDAC6,8 (IC50>1000 nM), CDK1 (IC50: 8.63 nM), CDK4,6,7 (IC50>1000 nM), CDK2 (IC50: 0.30 nM), CDK4,6,7 (IC50>1000 nM). CDK2 (IC50: 0.30 nM), CDK4,6,7 (IC50>1000 nM). CDK/HDAC-IN-2 can arrest the cell cycle in G2/M phase and induce apoptosis. CDK/HDAC-IN-2 has excellent anti-proliferative effects and shows significant anti-tumor effects.

VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.

8alpha-(2-Methylacryloyloxy)hirsutinolide 13-O-acetate shows inhibitory activity toward CYP2A6 and MAO-A and MAO-B enzymes.

1-Palmitoyl-2-13(S)-HpODE-sn-glycero-3-PC is a phospholipid featuring palmitic acid at the sn-1 position and 13(S)-HpODE at the sn-2 position.

CDK2-IN-13 is a potent Cyclin-dependent kinase 2 (CDK2) inhibitor (IC50 value: 12 µM).CDK2-IN-13 is involved in cell cycle regulation and can arrest the cell cycle. CDK2-IN-13 prevents cell division and proliferation, induces apoptosis, and can be used in cancer research.